ES2194860T3 - Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada. - Google Patents

Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada.

Info

Publication number
ES2194860T3
ES2194860T3 ES94901265T ES94901265T ES2194860T3 ES 2194860 T3 ES2194860 T3 ES 2194860T3 ES 94901265 T ES94901265 T ES 94901265T ES 94901265 T ES94901265 T ES 94901265T ES 2194860 T3 ES2194860 T3 ES 2194860T3
Authority
ES
Spain
Prior art keywords
timosine
suffer
patients
treatment
intended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94901265T
Other languages
English (en)
Inventor
Paul B Chretien
Milton G Mutchnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Sciclone Pharmaceuticals LLC
Original Assignee
Wayne State University
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University, Sciclone Pharmaceuticals LLC filed Critical Wayne State University
Priority claimed from PCT/US1993/010619 external-priority patent/WO1995012405A1/en
Application granted granted Critical
Publication of ES2194860T3 publication Critical patent/ES2194860T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

UN METODO Y UNA COMPOSICION PARA TRATAR UN PACIENTE CON HEPATITIS B QUE TIENE UNA DESCOMPENSACION HEPATICA UTILIZA CANTIDADES REDUCTORAS DE VIRUS DE HEPATITIS B DE T{SUB,{AL}1}, ADMINISTRANDOSELO A UN PACIENTE QUE TIENE UNA ENFERMEDAD DE RIÑON DESCOMPENSADA DE MANERA QUE EL PACIENTE ES SERONEGATIVO PARA EL ADN DEL VIRUS DE LA HEPATITIS B.
ES94901265T 1993-11-05 1993-11-05 Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada. Expired - Lifetime ES2194860T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1993/010619 WO1995012405A1 (en) 1993-11-05 1993-11-05 Method and composition for treatment of patients having decompensated liver disease

Publications (1)

Publication Number Publication Date
ES2194860T3 true ES2194860T3 (es) 2003-12-01

Family

ID=22237139

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94901265T Expired - Lifetime ES2194860T3 (es) 1993-11-05 1993-11-05 Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada.

Country Status (11)

Country Link
EP (1) EP0731710B1 (es)
KR (1) KR100298859B1 (es)
CA (1) CA2175337C (es)
DE (1) DE69332982T2 (es)
DK (1) DK0731710T3 (es)
ES (1) ES2194860T3 (es)
HK (1) HK1021685A1 (es)
MX (1) MXPA94003453A (es)
MY (1) MY111342A (es)
NO (1) NO961775D0 (es)
PT (1) PT731710E (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (es) * 1991-09-13 1994-05-21 Paul B Chretien
SG64892A1 (en) * 1992-02-06 1999-05-25 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
WO1994001125A1 (en) * 1992-07-13 1994-01-20 Sherman Kenneth E Composition and method of treating hepatitis b

Also Published As

Publication number Publication date
EP0731710A1 (en) 1996-09-18
MXPA94003453A (es) 2004-08-16
KR100298859B1 (ko) 2001-10-22
MY111342A (en) 1999-11-30
CA2175337A1 (en) 1995-05-11
DE69332982T2 (de) 2004-09-09
HK1021685A1 (en) 2000-06-23
NO961775L (no) 1996-05-02
CA2175337C (en) 2000-06-20
PT731710E (pt) 2003-09-30
DK0731710T3 (da) 2003-06-16
EP0731710B1 (en) 2003-05-14
DE69332982D1 (de) 2003-06-18
NO961775D0 (no) 1996-05-02
EP0731710A4 (en) 1999-12-22
KR960706352A (ko) 1996-12-09

Similar Documents

Publication Publication Date Title
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
ES2186660T3 (es) Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ATE83374T1 (de) Neue galenische form von fenofibrat.
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
ES2089923T3 (es) Composicion de vacuna subunitaria recombinante viva y procedimiento de preparacion.
BR0109716A (pt) Uso de um nucleosìdeo ou um análogo de nucleosìdeo no tratamento de infecção viral por hepatite delta
DE3850154T2 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
SE7900136L (sv) Flytbarhetshjelpmedel
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
PT1115420E (pt) Tratamento de infeccao de hepatite b com timosina alfa 1 e lamivudine
ES2194860T3 (es) Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada.
ES2211996T3 (es) Agentes de union a receptores de acido hialuronico y su uso para el tratamiento de tumores o de reestenosis.
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
EA199800819A1 (ru) Способ лечения биполярного расстройства
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
GB9106278D0 (en) Method of treatment
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина
DE69210737D1 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
ES2137513T3 (es) Utilizacion de hierro aplicable por via intravenosa para la terapia de enfermedades tumorales y/o enfermedades infecciosas.
KR970019821A (ko) 송진을 함유한 치약 제조 방법
ATE332704T1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon